Radiopharmaceuticals Analysis for Detailed Insights And INternational Tracking of Safety (RADIANTS)

Caen University Hospital

Status: Active, not recruiting

Conditions: Side Effect of Drug; Cancer

Treatments: Drug: Radiopharmaceuticals drugs

Study type: Observational

Funder types: Other

Identifiers

NCT06483685

20240531

RADIANTS (Other Identifier)

Details and patient eligibility

About

Little is known about cancer therapy-related radiopharmaceuticals drugs safety. Here the investigators use VigiBase (http://www.vigiaccess.org/), the World Health Organization (WHO) database of individual safety case reports, to identify and describe cases of cancer therapy-related radiopharmaceuticals drugs.

Full description

Radiopharmaceuticals drugs especially for therapeutic purposes are responsible of a wide range of side effects. The investigators use VigiBase, the World Health Organization (WHO) database of individual safety case reports, to identify cases of adverse drug reactions following treatment with radiopharmaceuticals drugs.

Enrollment: 500,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• cases reported in the World Health Organization (WHO) database of individual safety case reports (vigibase)

Exclusion criteria

• not related to radiopharmaceuticals

Trial design

500,000 participants in 1 patient group

Adverse Events with Radiopharmaceuticals drugs

Description:

Cases reported in the World Health Organization (WHO) of patients treated by Radiopharmaceuticals drugs with reported toxicity

Treatment:

Drug: Radiopharmaceuticals drugs